These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38159338)

  • 21. Successful transfer of stable patients on opioid agonist therapies from specialty addiction treatment to primary care settings in Ukraine: A pilot study.
    Meteliuk A; Galvez S; Fomenko T; Kalandiia H; Iaryi V; Farnum SO; Islam Z; Altice FL; Madden LM
    J Subst Abuse Treat; 2022 Mar; 134():108619. PubMed ID: 34579978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of expanding opioid agonist therapies on the HIV epidemic and mortality in Ukraine: a modelling study.
    Tan J; Altice FL; Madden LM; Zelenev A
    Lancet HIV; 2020 Feb; 7(2):e121-e128. PubMed ID: 31879250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retention in medication-assisted treatment programs in Ukraine-Identifying factors contributing to a continuing HIV epidemic.
    Dumchev K; Dvoryak S; Chernova O; Morozova O; Altice FL
    Int J Drug Policy; 2017 Oct; 48():44-53. PubMed ID: 28800420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Navigating Opioid Agonist Therapy among Young People who use Illicit Opioids in Vancouver, Canada.
    Pilarinos A; Kwa Y; Joe R; Thulien M; Buxton JA; DeBeck K; Fast D
    Int J Drug Policy; 2022 Sep; 107():103773. PubMed ID: 35780565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of access to integrated services at opioid agonist treatment sites in reaching 90-90-90 cascade in people who inject drugs in Ukraine: Country-level data.
    Meteliuk A; Prokhorova T; Filippovych S; Ompad DC; Zaller N
    Drug Alcohol Depend; 2020 Nov; 216():108216. PubMed ID: 32805547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors associated with physical and sexual violence by police among people who inject drugs in Ukraine: implications for retention on opioid agonist therapy.
    Kutsa O; Marcus R; Bojko MJ; Zelenev A; Mazhnaya A; Dvoriak S; Filippovych S; Altice FL
    J Int AIDS Soc; 2016; 19(4 Suppl 3):20897. PubMed ID: 27435717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Should I Stay or Should I Go? A Qualitative Exploration of Stigma and Other Factors Influencing Opioid Agonist Treatment Journeys.
    Carlisle VR; Maynard OM; Bagnall D; Hickman M; Shorrock J; Thomas K; Kesten J
    Int J Environ Res Public Health; 2023 Jan; 20(2):. PubMed ID: 36674280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine.
    Marcus R; Bojko MJ; Mazhnaya A; Makarenko I; Filippovych S; Dvoriak S; Altice FL; Springer SA
    J Subst Abuse Treat; 2018 Mar; 86():86-93. PubMed ID: 29415856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. "You'll come in and dose even in a global pandemic": A qualitative study of adaptive opioid agonist treatment provision during the COVID-19 pandemic.
    Conway A; Treloar C; Crawford S; Degenhardt L; Dore GJ; Farrell M; Hayllar J; Grebely J; Marshall AD
    Int J Drug Policy; 2023 Apr; 114():103998. PubMed ID: 36907071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimising treatment in opioid dependency in primary care: results from a national key stakeholder and expert focus group in Ireland.
    Van Hout MC; Crowley D; McBride A; Delargy I
    BMC Fam Pract; 2018 Jun; 19(1):103. PubMed ID: 29960593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary healthcare-based integrated care with opioid agonist treatment: First experience from Ukraine.
    Morozova O; Dvoriak S; Pykalo I; Altice FL
    Drug Alcohol Depend; 2017 Apr; 173():132-138. PubMed ID: 28242537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine.
    Meteliuk A; Galvez de Leon SJ; Madden LM; Pykalo I; Fomenko T; Filippovych M; Farnum SO; Dvoryak S; Islam ZM; Altice FL
    J Subst Abuse Treat; 2021 Feb; 121():108164. PubMed ID: 33191004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis.
    Stone J; Degenhardt L; Grebely J; Larney S; Altice FL; Smyrnov P; Rahimi-Movaghar A; Alavi M; Young AM; Havens JR; Miller WC; Hickman M; Vickerman P
    Lancet Psychiatry; 2021 Apr; 8(4):301-309. PubMed ID: 33640039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report.
    Crowley D; Delargy I
    Harm Reduct J; 2020 Jul; 17(1):49. PubMed ID: 32680520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers.
    Stopka TJ; Rottapel RE; Ferguson WJ; Pivovarova E; Toro-Mejias LD; Friedmann PD; Evans EA
    Int J Drug Policy; 2022 Dec; 110():103803. PubMed ID: 35965159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions.
    Bouck Z; Scheim AI; Gomes T; Ling V; Caudarella A; Werb D
    Int J Drug Policy; 2022 Jun; 104():103680. PubMed ID: 35447476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, implementation and preliminary results of a type-2 hybrid cluster-randomized trial of integrating screening and treatment for major depressive disorder into specialty clinics providing opioid agonist therapies in Ukraine.
    Machavariani E; Bromberg DJ; Dumchev K; Dvoriak S; Zeziulin O; Morozova O; Esserman D; Pykalo I; Saichuk N; Ivasiy R; Haddad MS; Altice FL
    Contemp Clin Trials; 2023 Aug; 131():107248. PubMed ID: 37263492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy.
    Moallef S; DeBeck K; Fairbairn N; Cui Z; Brar R; Wilson D; Johnson C; Milloy MJ; Hayashi K
    Addict Sci Clin Pract; 2022 Dec; 17(1):73. PubMed ID: 36522789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stigma and quality of co-located care for HIV-positive people in addiction treatment in Ukraine: a cross-sectional study.
    Sereda Y; Kiriazova T; Makarenko O; Carroll JJ; Rybak N; Chybisov A; Bendiks S; Idrisov B; Dutta A; Gillani FS; Samet JH; Flanigan T; Lunze K
    J Int AIDS Soc; 2020 May; 23(5):e25492. PubMed ID: 32372534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying the most common barriers to opioid agonist treatment in an Australian setting.
    Hall NY; Le L; Abimanyi-Ochom J; Teesson M; Mihalopoulos C
    Aust J Prim Health; 2023 Oct; 29(5):445-454. PubMed ID: 36934460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.